Stelerix Web Blog Knowledge at your Fingertips

11Feb/110

Healthcare Cost Containment in Europe

The scenario is somewhat bleak, or at least that's what Ulf Staginnus, Head of health economics in Europe at Novartis Oncology had to say.

We'll have the whole interview up on the main site, shortly. For now, enjoy this:

Best regards,

Jeff

18Jan/110

Call for Questions.

We have an interview upcoming with Vivek Shukla, later next week.

His 12  years of experience serving over 40 reputable clients in the Indian pharmaceutical industry have given him a grasp of strategic business knowledge that is unrivaled.

Now is your chance to pick the brains of a world-class expert. Comment or send questions to info@stelerix.com

Posted by Jeff

18Jan/110

Exclusive On-Demand Webinar, Free! Atul Sharma – Global Partnerships

If you have not yet read or listened, check this out!

Atul Sharma, Senior Manager at Alembic Limited took some time to speak with me about his expansive experiences in a diverse array of emerging and mature markets.

We discuss a number of issues in-depth, like understanding local success drivers and why innovation is especially important in generic formulations.

There are lots more similar interviews coming up, so submit your questions if you want to hear from experts!

Posted by Jeff

13Jan/110

Call for Questions!

I have a number of interviews coming up.  I am really excited to have the opportunity to speak to experienced stakeholders. It is bound to be one engaging and informing discussion after another.

Get ready for a flood of quality content in the latter half of next week.

I have done my best to think up intriguing questions. They are all based on direct input from our preliminary research and direct industry stakeholder input, like this. But I'm still new to the interview game. So if you have ideas or are burning for answers, please send them to us!

If you could pick the brain of an emerging market expert, what would you ask?

If you need some inspiration, here are some tried and true questions (and answers).

Alok Kumar, Part 1, Part 2 (FREE On-Demand webinar)

Vivek Varma - Contract Manufacturing

Posted by Jeff

12Jan/110

Exclusive Interview, Part 2

I woke up at 3:30am (2:00pm IST) the other day, to find out about lessons learned  in competitive generic global product launches.

The follow-up to our first exclusive interview is now online.

Watch this FREE, on-demand webinar to understand:

  • What the Indian market will look like in ten years
  • What differentiates it from
  • Strategies for generics success.
  • How to deal with regulatory hurdles and surprises.

It's our first attempt at supplementing an audio call with powerpoint presentations and a full minute-by-minute note-guide. We are very eager to improve and should have a version with improved sound quality up by tomorrow. Your comments and thoughts are encouraged.

FREE On-Demand Webinar - Alok Kumar discusses what is required for generics success in India, and the world.

Posted by Jeff

6Jan/110

Merck Moves In

It is always encouraging to see the big players making aggressive moves into a market. The announcement then, that Merck KgaA is setting up an Indian technology centre to provide contract development services for a large range of applications, is exactly what we like to hear. That it's part of an ongoing initiative is even more exciting.

Some of Merck's other innovative initiatives, such as the one below, present very interesting soft opportunities that will also benefit rising executives in emerging markets. And not just in job-specific technical roles. Access to the seasoned experiences of others is something that we predicate our own business on (see: interviews with experts) and another hidden benefit of globalization.

Posted by Jeff

UPDATE: Brought to our attention by our good friend, @andrealmarch is this fantastic Globe and Mail article: Ten tips for success in India

24Dec/100

Trade Traction.

45% of India's USD 22 billiion pharmaceutical industry obtains revenue from exporting generic drugs. Understandably then, it's exciting to see progress in India's trade spat with the EU over generic drugs.

With so much on the line, it makes sense why resolution is important. And an admission of guilt by the EU at this month's Brussels Summit is a concrete and promising step forward.